Aon invests in eMed to expand GLP-1 weight management solutions

Published 18/08/2025, 14:38
Aon invests in eMed to expand GLP-1 weight management solutions

DUBLIN - Aon plc (NYSE:AON), a $79 billion market cap insurance and consulting giant with a strong track record of dividend payments for 46 consecutive years, announced Monday a strategic investment in eMed Population Health, Inc., a provider of GLP-1 therapy programs for weight management. The investment aims to enhance employer-sponsored access to these therapies. According to InvestingPro analysis, Aon currently trades near its Fair Value, demonstrating the company’s solid market positioning.

The partnership follows Aon’s implementation of eMed’s GLP-1 weight management program for its U.S. workforce earlier this year. According to the company, the program has shown positive results with more than 1,200 registrants, an average weight loss of 22.4 pounds per participant, and a 95 percent retention rate over six months. This initiative aligns with Aon’s robust financial performance, featuring 18.3% revenue growth over the last twelve months and maintaining a healthy current ratio of 1.03.

"This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace," said Lisa Stevens, Chief Administrative Officer for Aon.

eMed’s platform combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and adherence support. With this investment, the company plans to expand its provider network and behavioral health tools.

Linda Yaccarino, CEO of eMed Population Health, Inc., described the partnership as "a win for both payers and participants."

In April, Aon released findings from a multi-year analysis of U.S. commercial health claims data regarding GLP-1 medications for obesity management.

"We know that GLP-1s are not a one size fits all strategy," said Farheen Dam, Head of Health for North America at Aon.

The financial terms of the investment were not disclosed in the press release statement. InvestingPro data shows Aon maintains a GOOD overall financial health score, with particularly strong profitability metrics. For deeper insights into Aon’s financial position and future prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, covering over 1,400 top US stocks with expert analysis and actionable intelligence.

In other recent news, Aon is facing a lawsuit in Delaware bankruptcy court over alleged fraud related to its marketing of credit insurance for start-ups. This legal challenge comes as Aon has been expanding into the credit insurance market since 2020. Meanwhile, Jefferies has upgraded Aon’s stock rating from Hold to Buy, citing potential for margin expansion due to favorable organic growth, productivity gains, and cost savings. The price target has been raised to $426.00, suggesting a 21% potential upside. Additionally, Aon has appointed David DeBrunner as its Chief Accounting Officer, effective September 15, 2025. DeBrunner will report to Edmund Reese, the company’s CFO. In corporate governance updates, Aon shareholders have approved all proposals at the 2025 Annual General Meeting, including the election of 12 directors and amendments to the incentive plan. Furthermore, Aon has launched the AI-powered Aon Broker Copilot platform to enhance the insurance placement process through predictive analytics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.